RAC 2.20% $1.78 race oncology ltd

General Comments / Chat, page-10296

  1. 456 Posts.
    lightbulb Created with Sketch. 689
    ...Unless we think we can get IND approval from the P1 data (CPACS).

    Primary endpoints: Safety & optimal Phase 2 dose
    Exploratory endpoints: Standard & advanced cardiac markers including VO2Peak, m6A RNA levels, & anticancer efficacy
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.